Search company, investor...
Macrophage Pharma company logo

Macrophage Pharma


Series A - II | Alive

Total Raised


About Macrophage Pharma

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Company's technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body's natural immune system to fight cancer.

Headquarters Location

Gainsborough House, 59-60 Thames Street Windsor

Berkshire, England, SL4 1TX,

United Kingdom

Missing: Macrophage Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Macrophage Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Macrophage Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Macrophage Pharma is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

1,568 items

Macrophage Pharma Patents

Macrophage Pharma has filed 3 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Autoimmune diseases
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, Immune system, Transcription factors, Interleukins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Interleukins



Latest Macrophage Pharma News

Macrophage Pharma Appoints Dr Venkat Reddy As Chief Executive Officer

Jun 1, 2021

Macrophage Pharma Appoints Dr Venkat Reddy As Chief Executive Officer Executive leadership and strategic focus strengthened for sustained company development Author: Jun 1, 2021 3:00 AM EDT WINDSOR, England, June 1, 2021 /PRNewswire/ -- Macrophage Pharma Limited ('MPL'), a company focused on the discovery and early stage development of highly novel small molecule therapeutics with the potential to transform outcome in inflammation, autoimmune disease and cancer through regulation of innate immune response, announced today that its Chief Scientific Officer (CSO), Dr Venkat Reddy PhD, has been appointed by the Board as Chief Executive Officer (CEO). Commenting on the appointment, Dr Michael Moore, Chairman of Macrophage Pharma, said: "The Board is delighted to have promoted Venkat to CEO. Since joining the Company, Venkat's influence in combining a strategic biology focus on targets critical for regulated cell death in immune-mediated diseases with the Company's drug discovery platform based on proprietary  Esterase Sensitive Motif™ (ESM™) technology, has been transformative, enhancing the opportunity for commercialisation of our novel small molecule assets for a variety of protein targets and therapeutically unmet diseases." Dr Venkat Reddy, CEO of Macrophage Pharma, commented: "I am honoured to have been appointed CEO of Macrophage Pharma. The potential of our ESM™ technology platform to generate novel drugs is compelling as demonstrated by its ability to impact adaptive immunity through selective modulation of myeloid derived innate immune cells. I look forward to continuing my work with Macrophage Pharma's executive team and Board of Directors to unlock the full therapeutic and commercial potential of the technology across a spectrum of human diseases." Venkat Reddy has a successful track record and extensive strategic and management experience from senior executive roles in both European and US biotech and pharma, including Glenmark Pharmaceuticals (SVP, Global Head of Translational Sciences), Pfizer (Senior Director, Strategic Alliances and Partnerships, Centers for Therapeutic Innovation), Sanofi (Senior Director, Head, Bio-Innovation France: Global Biotherapeutics) and Novartis (Group leader, GNF). Venkat holds a PhD from the Ludwig-Maximilians Universität München and undertook post-doctoral studies in immunology and oncology at the Scripps Research Institute. He has served Macrophage Pharma as Chief Scientific Officer since January 2020. About Macrophage Pharma Macrophage Pharma Limited (MPL) is developing transformative first in class small molecule therapeutics that precisely control or enhance immune responses across disease indications. Utilizing MPL's proprietary  Esterase  Sensitive  Motif technology (ESM TM), its first in class therapeutics target the innate immune system in a highly selective manner. The ESM™ platform together with expanded variants of this foundation technology in evolution within MPL, are designed to deliver small molecule drugs selectively, not only to macrophages but also to other cell types expressing the relevant carboxylesterase isoform. The Company's R&D pipeline is focused on the targeting of key regulatory proteins in chronic inflammation-inducing pathways, such as necroptosis, pyroptosis and inflammasome to address unmet medical need. The Company was founded by the CRT Pioneer Fund (CPF) and is backed by CPF, Aglaia Oncology Fund II, Novo Holdings A/S and M Ventures. Please visit the company website for further information: View original content:

Macrophage Pharma Frequently Asked Questions (FAQ)

  • Where is Macrophage Pharma's headquarters?

    Macrophage Pharma's headquarters is located at Gainsborough House, 59-60 Thames Street, Berkshire.

  • What is Macrophage Pharma's latest funding round?

    Macrophage Pharma's latest funding round is Series A - II.

  • How much did Macrophage Pharma raise?

    Macrophage Pharma raised a total of $10.96M.

  • Who are the investors of Macrophage Pharma?

    Investors of Macrophage Pharma include M Ventures, Aglaia Oncology Funds, Cancer Research Technology and Novo Seeds.

  • Who are Macrophage Pharma's competitors?

    Competitors of Macrophage Pharma include Pionyr Immunotherapeutics, Neon Therapeutics, Forty Seven, NextCure, Harpoon Therapeutics and 9 more.

Compare Macrophage Pharma to Competitors

OncoResponse Logo

OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to increase the success rate of these therapies across multiple cancer types.

ImmunoMet Therapeutics

ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop anti-tumor and immuno-oncology therapies.

Immune-Onc Therapeutics Logo
Immune-Onc Therapeutics

Immune-Onc provides biological services. The company helps cancer patients through cancer immunotherapy and biological development treatments including tumor microenvironment and immune suppressive pathways to develop biotherapeutics. Immune-Onc was founded in 2016 and is based in Palo Alto, California.

Fortis Therapeutics

Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody-drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.

Pionyr Immunotherapeutics Logo
Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.


Epsilogen is engaged in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumors including greater potency, enhanced tumor access, and a long tissue half-life.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.